๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenyang
Clinical trial register · China

Clinical Trials in Shenyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shengjing Hospital46 General Hospital of Shenyang Military Region33 First Hospital of China Medical University21 China Medical University, China13 AstraZeneca12
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenyang

419 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
NCT07239245Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
Health Behavior Change in High-Risk Colorectal Cancer Individuals
NCT07262840Health Behavior, Colorectal Neoplasms, Primary Prevention/Methods
China Medical University, China
Not applicable
80
Shenyang
2025-11-10
Recruiting
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo
NCT07712523Adult Subjects With Non-Segmental Vitiligo
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase 2
200
Shenyang
2025-11-05
Active, closed
Research on the Effectiveness of Remote Rehabilitation l for Shoulder and Neck Recovery in Oral Cancer Patients After Selective Neck Dissection
NCT07504809Oral Cancer Patients After Selective Neck Dissection
Pai Pang
Not applicable
80
Shenyang
2025-10-28
Not yet open
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
NCT07175233Atopic Dermatitis (AD)
DrugSIM0278
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2
184
Hangzhou, Shenyang
2025-10-27
Active, closed
ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate to Severe Coronary Artery Calcification
NCT07340294Coronary Artery Calcification, Calcific Coronary Arteriosclerosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Active, closed
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer
DrugsPertuzumab·Trastuzumab Rezetecan·Trastuzumab·Carboplatin
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
740
Shenyang, Shanghai
2025-10-23
Recruiting
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07373964Small Cell Lung Cancer
China Medical University, China
Phase 2
36
Shenyang
2025-10-15
Recruiting
Local Hyperthermia Combined With Topical 3% Hydrogen Peroxide for Refractory Viral Warts
NCT07565350Refactory Warts
First Hospital of China Medical University
Not applicable
80
Shenyang
2025-10-01
Recruiting
CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
NCT07193667Relapsed/Refractory Autoimmune Diseases
ShenZhen Cell Valley
Not applicable
3
Shenyang
2025-10
Recruiting
Application of โถโธGa-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
NCT07144085Tumor, Metastatic Cancer
Yi Tian
Phase 1
30
Shenyang
2025-09-11
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
NCT07113262Thyroid Eye Disease
DrugIBI311
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
111
Shenyang
2025-09-10
Recruiting
Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
NCT07160491STEMI - ST Elevation Myocardial Infarction
Shenyang Northern Hospital
Not applicable
3,356
Shenyang
2025-09-08
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Head dOwn Position Before Endovascular Treatment for Large veSsel Occlusion (HOPES5)
NCT07172789Ischemic Stroke
General Hospital of Shenyang Military Region
Not applicable
210
Shenyang
2025-09-02
Not yet open
RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged โ‰ฅ50 Years in China
NCT07075029Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsUtidelone·Oxaliplatin·Capecitabine
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsLeucovorin·Oxaliplatin·Capecitabine·Cisplatin
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
NCT07122687Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
DrugsIBI363·Pemetrexed·Cisplatin·Carboplatin
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
170
Shenyang
2025-08-26
Recruiting
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
NCT07097818Type 1 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
600
Shenyang, Shanghai
2025-08-18
Recruiting
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study
NCT07284264Dementia
Xuanwu Hospital, Beijing
Observational
6,000
Beijing, Hainan, Ningxiang, Shenyang, Shenzhen, Yichun
2025-08-15
Active, closed
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
NCT07122063Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
266
Shenyang
2025-08-11
Recruiting
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)
Xueyan Zhao
Observational
12,154
Zhengzhou, Shenyang, Beijing
2025-08-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Not yet open
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575Interstitial Lung Abnormalities
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Not yet open
Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD
NCT07088744Gastric Cancer (Diagnosis), Gastric High-grade Intraepithelial Neoplasia, Gastric Low-grade Intraepithelial Neoplasia, Gastritis
Changhai Hospital
Observational
169
Nanning, Shenyang, Chengdu, Shanghai
2025-07-30
Active, closed
A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD Patients
NCT07331402COPD Patients
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
12
Shenyang
2025-07-28
Recruiting
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
NCT07506057Urothelial Carcinoma, Biliary Tract Cancer, HER2
DrugsSerplulimab·Trastuzumab
Xiujuan Qu
Phase 2
20
Shenyang
2025-07-15
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
DrugsWJB001·Niraparib·Carboplatin·Bevacizumab
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
NCT07202728Hydatidiform Mole
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia
NCT06507488Cerebrovascular Disorders
First People's Hospital of Shenyang
Not applicable
206
Shenyang
2025-07-07
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
NCT07657130Breast Cancer Females
Liaoning Cancer Hospital & Institute
Phase 2
120
Shenyang
2025-07-01
Active, closed
18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC
NCT07449858Non Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
DrugsAAA817·ARPI
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
Total Energy Expenditure in Healthy Chinese Populations: A Nationwide Study Using the Doubly Labelled Water Method
NCT07178054Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
240
Chongqing, Shenzhen, Haikou, Hohhot, Shenyang, Qingdao, Tacheng
2025-07-01
Not yet open
Daoyin Technique for Improving Exercise Endurance in IPF
NCT07019714Idiopathic Pulmonary Fibrosis
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Not applicable
236
Shenyang
2025-06-30
Recruiting
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
NCT06483737Overt Hepatic Encephalopathy
DrugsBranched-Chain Amino Acids·Lactulose·Rifaximin
General Hospital of Shenyang Military Region
Not applicable
174
Shenyang
2025-06-24
Recruiting
Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
NCT06922669Drug Induced Liver Injury
General Hospital of Shenyang Military Region
Not applicable
232
Shenyang
2025-06-24
Active, closed
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
NCT06941792Coronary Heart Disease
DrugInclisiran sodium
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839Macular Edema
Boehringer Ingelheim
Phase 2
300
Chengdu, Shanghai, Shenyang, Shijiazhuang, Taiyuan
2025-06-05
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugSAR442970
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions
NCT06994416Mammary Tumor, Nipple Discharge
The Fourth Affiliated Hospital of China Medical University
Observational
300
Shenyang
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, รœrรผmqi
2025-06-01
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
DrugsJS007·JS207
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
DrugsCis-platinum·Afatinib·Penpulimab·Pemetrexed
Akeso
Phase 1/2
230
Shenyang
2025-05-21
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
NCT06880276Atopic Dermatitis
Qilu Pharmaceutical Co., Ltd.
Phase 3
360
Shenyang
2025-05-16
Recruiting
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
NCT07034391Non-Small Cell Lung Cancer
China Medical University, China
Phase 2
40
Shenyang
2025-05-12
Not yet open
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
NCT06951841Small Cell Lung Cancer
DrugsAnlotinib·Tislelizumab
China Medical University, China
Phase 4
31
Shenyang
2025-04-30
Recruiting
The Effect of Situation Puzzle Games on Nursing Students' Death Anxiety and Meaning in Life
NCT06991621Death Anxiety
China Medical University, China
Not applicable
70
Shenyang
2025-04-21
By invitation
Pseudomonas Aeruginosa Injection Combined With Polyvinylpyrrolidone-Iodine in Immediate Breast Reconstruction Surgery With Implants
NCT07460297Postoperative Seroma Rate, Drainage Tube Removal Time, and Capsular Contracture Rate, Seroma Following Procedure
Jianyi Li
Not applicable
100
Shenyang
2025-04-16
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugNRT6003
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Recruiting
Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke
NCT06931535Ischemic Stroke
General Hospital of Shenyang Military Region
Not applicable
1,600
Shenyang
2025-04-13
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
DrugsLM-108·Penpulimab·Gemcitabine Hydrochloride·Paclitaxel
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
EBUS-TTFB vs EBUS-TBNA for Diagnosing Inadequate Lymph Node Specimens Based on MOSE
NCT06913569Lymphadenopathy
Shanghai Chest Hospital
Not applicable
162
Shenyang, Shanghai, Huizhou
2025-04-01
Recruiting
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
NCT07185503Mucormycosis in Hematologic Malignancies
DrugLiposomal Amphotericin B
Institute of Hematology & Blood Diseases Hospital, China
Observational
60
Dalian, Harbin, Shenyang, Tianjin
2025-03-25
Active, closed
Plasma Multi - Omics Detection for Evaluating Efficacy and Recurrence Risk in Oligometastatic Colorectal Cancer Conversion Therapy
NCT07492238Colorectal Cancer
Xiujuan Qu
Not applicable
120
Shenyang
2025-03-20
Recruiting
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
NCT06940102Cachexia, Digestive System Cancer, Gastric Cancer, Colorectal Cancer
DrugNano-crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Observational
120
Shenyang
2025-03-12
Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension
NCT06970509Esophageal Varices, Portal Hypertension
Shanghai Zhongshan Hospital
Observational
1,450
Guangzhou, Nanchang, Shenyang, Jinan, Shanghai
2025-03-01
Not yet open
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
NCT06820762SCLC
DrugIrinotecan liposome
The Second Affiliated Hospital of Dalian Medical University
Phase 2
40
Dalian, Shenyang
2025-02-28
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
DrugAAA817
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai
2025-02-26
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
NCT06601127Ischemic Stroke
DrugClopidogrel
Tianjin Institute of Pharmaceutical Research Co., Ltd
Phase 2
600
Shenyang, Beijing
2025-02-21
Recruiting
Balloon Angioplasty for Minor Unstable Stroke With IntraCranial Atherosclerosis Stenosis (BAMUS-ICAS)
NCT06763458Ischemic Stroke
General Hospital of Shenyang Military Region
Not applicable
100
Shenyang
2025-02-19
Recruiting
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
NCT06696417Moderate to Severe Plaque Psoriasis
First Hospital of China Medical University
Observational
1,516
Shenyang
2025-02-17
Recruiting
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
NCT06717750Advanced Malignant Solid Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1
102
Beijing, Shenyang
2025-02-13
Recruiting
Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus
NCT06821399Diabetes, Diabetic Retinopathy, Type 2 Diabetes Mellitus (T2DM)
Yufan Wang
Observational
2,920
Lanzhou, Shanghai, Shenyang
2025-02-01
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025Asthma
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
DrugsRemibrutinib A·Remibrutinib B
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Recruiting
Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
NCT06830018Cancer-related Fatigue๏ผŒ Gastric Cancer๏ผŒColorectal Cancer๏ผŒNano-crystalline Megestrol Acetate๏ผŒMegestrol Acetate๏ผŒFirst-line Treatment
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
76
Shenyang
2025-01-23
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189Marginal Zone Lymphoma(MZL)
DrugOrelabrutinib
Ruijin Hospital
Phase 2
145
Shanghai, Shenyang, Beijing
2025-01-23
Recruiting
Near-Infrared Imaging of Motor Imagery Effects in Spinal Cord Injury
NCT07106060SCI - Spinal Cord Injury, Motor Imagery, Brain-Computer Interfaces
Shengjing Hospital
Not applicable
36
Shenyang
2025-01-01
Recruiting
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
NCT06779058Chronic Hepatitis B, Liver Fibrosis
Shengjing Hospital
Observational
600
Shenyang
2025-01-01
Recruiting
Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
NCT07097805Type 1 Diabetes (T1D)
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Recruiting
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer, Colorectal Cancer
JiaRay Group
Phase 1
94
Harbin, Shenyang
2024-12-31
By invitation
Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
NCT06881550Breast Cancer
Caigang Liu
Not applicable
2,000
Shenyang
2024-12-30
Recruiting
The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation
NCT07085650Atrial Fibrillation (AF), Mitral Regurgitation, Tricuspid Regurgitation
First Hospital of China Medical University
Observational
2,000
Shenyang
2024-12-30
Recruiting
Effect of Threshold Pressure-Loaded RMT + tTBS on Respiratory Function in SCI Patients
NCT07050069Spinal Cord Injuries
Shengjing Hospital
Not applicable
60
Shenyang
2024-12-25
Recruiting
fNIRS-Driven Visual Feedback Training to Restore Walking After Stroke
NCT07014891Stroke
Shengjing Hospital
Not applicable
44
Shenyang
2024-12-15
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
DrugBelimumab
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Not yet open
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
NCT06666166Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
Yunpeng Liu
Phase 2
28
Shenyang
2024-12
Not yet open
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT06663254Perioperative Volume Replacement, Hydroxyethyl Starch
Xiangya Hospital of Central South University
Phase 4
410
Zhengzhou, Changsha, Shenyang, Jinan, Xi'an, Beijing
2024-11-30
Active, closed
Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities
NCT04077086Refractive Errors
Queen's University, Belfast
Not applicable
10,000
Shenyang, Yinchuan
2024-11-28
Recruiting
Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
NCT06971211Metastatic Castration-resistant Prostate Cancer
DrugIMRT
Jianbin Bi
Phase 2
40
Shenyang
2024-11-27
Recruiting
The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
NCT06698679Breast Cancer
Shengjing Hospital
Observational
1,000
Shenyang
2024-11-15
Recruiting
The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer
NCT06690645Breast Cancer
Shengjing Hospital
Observational
840
Shenyang
2024-11-15
Active, closed
Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas
NCT06678373Japanese Encephalitis
Liaoning Chengda Biotechnology CO., LTD
Phase 4
250
Shenyang
2024-11-14
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Capox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
By invitation
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NCT07059819Cervical Intraepithelial Neoplasia (CIN), Human Papillovirus
First Hospital of China Medical University
Not applicable
400
Shenyang
2024-11-02
By invitation
Sleep Improvement Therapy Affects Pregnancy Outcomes in Chinese Singletons and Twins by Improving Sleep Quality
NCT06687044Gestational Diabetes, Hypertension in Pregnancy, Preterm Labor, NICU Infants
Jun Wei
Not applicable
300
Shenyang
2024-11-01
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
2024-10-29
Recruiting
Rapid dFLC Response Predict CHR in AL Amyloidosis
NCT06627309Systemic AL Amyloidosis
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Rows per page Showing 101–200 of 419
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenyang?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 419 of those studies with a site in Shenyang.

How many clinical trials are recruiting in Shenyang?

253 of the 419 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 55 have not yet opened recruitment, 101 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.